Advertisement
Advertisement
U.S. Markets close in 5 hrs 19 mins
Advertisement
Advertisement
Advertisement
Advertisement

Alpha Cognition Inc. (ACOGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4000+0.0150 (+3.90%)
As of 09:30AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3850
Open0.4000
BidN/A x N/A
AskN/A x N/A
Day's Range0.4000 - 0.4000
52 Week Range0.3850 - 1.8000
Volume300
Avg. Volume9,478
Market Cap25.212M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3780
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.75
  • GlobeNewswire

    Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing

    NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOGIN AT: https://bit.ly/3nbZJuOThe company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Companies are accepting 1x1 manag

  • Zacks Small Cap Research

    ACOGF: Resolving to Move Ahead

    By John Vandermosten, CFA OTC:ACOGF READ THE FULL ACOGF RESEARCH REPORT Bioavailability and Bioequivalence Study Results Alpha Cognition, Inc. (OTC:ACOGF) provided topline results from its bioavailability and bioequivalence (BABE) study in a June 22 nd press release which was followed by a conference call providing additional detail along with a presentation summarizing key data. Results showed

  • Business Wire

    Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease

    VANCOUVER, British Columbia, June 22, 2022--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from its pivotal bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).

Advertisement
Advertisement